Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (1)
  • Endogenous Metabolite
    (1)
  • HMG-CoA Reductase
    (1)
  • Others
    (11)
Filter
Search Result
Results for "

cholesterol acetate

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    12
    TargetMol | Activity
  • Natural Products
    4
    TargetMol | inventory
Cholesteryl Acetate
T2918604-35-3
Cholesteryl Acetate is a cholesterol ester obtained from the esterification of the hydroxyl group of cholesterol with acetic acid. It functions as a metabolite in the human body and is both a cholesterol ester and an acetate ester.
  • $29
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Ganoderal A
TN1655104700-98-3
The oxygenated sterols( 26-oxygenosterols ganoderol A, ganoderol B, ganoderal A, and ganoderic acid Y) from G. lucidum can inhibit cholesterol biosynthesis via conversion of acetate or mevalonate as a precursor of cholesterol.
    7-10 days
    Inquiry
    Lyso-Globotriaosylceramide (d18:1)
    T37291126550-86-5
    Lyso-globotriaosylceramide is a form of globotriaosylceramide that is lacking the fatty acyl group. It binds to Shiga toxin 1 (Stx1) in the presence of cholesterol and phosphatidylcholine but does not bind Stx2. It also reduces viability and aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate when used at concentrations of 50 and 1 μM, respectively. Lyso-globotriaosylceramide accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. It also accumulates in the urine, kidney, and plasma of patients with Fabry disease. Lyso-globotriaosylceramide levels decrease in response to administration of the α-galactosidase inhibitor 1-deoxygalactonojirimycin in a transgenic mouse model of Fabry disease. Decreases in plasma and urine concentrations of lyso-globotriaosylceramide have been used as a biomarker for efficacy of enzyme replacement therapy (ERT) and other therapies in the treatment of Fabry disease.
    • $2,228
    35 days
    Size
    QTY
    Meglutol
    T1664503-49-1
    Meglutol (3-Hydroxy-3-methylglutaric acid) is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids. It acts by interfering with the enzymatic steps involved in the conversion of acetate to hydroxymethyl glutaryl coenzyme A as well as inhibiting the activity of HYDROXYMETHYLGLUTARYL COA REDUCTASES which is the rate-limiting enzyme in the biosynthesis of cholesterol.
    • $45
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale